神经在线共30篇
排序
FDA Action Update, April 2024: Approvals, Clearance, and Complete Response Letter
The FDA was busy in April 2024, making a number of decisions on potential new therapeutic agents including granting approvals, a clearance, and a fast track designation, issuing a...
1年前
Navigating Challenges and Opportunities With AI Adoption in Neurological Practice: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN
WATCH TIME: 5 minutes'What I really wanted to highlight is that we should be thinking about equity, and access. Many solutions might have the ability to increase clinician efficien...
1年前
Cell Therapy Reveals Early Promise in Addressing Motor and Non-Motor Symptoms for Parkinson Disease
Claire Henchcliffe, MD(Credit: Weill Cornell Medicine)According to a recent report from GlobalData, using data from BlueRock Therapeutics’ phase 1 study (NTC04802733) assessing be...
1年前Recent Progress in Advancing Gene Therapy for Parkinson Disease: Russell Lonser, MD
WATCH TIME: 4 minutes'I think what gene therapy provides us is a new opportunity to really target the specific problem of the disease at its core.'AB-1005 (AskBio), an investigatio...
1年前
Understanding the Root of REM Behavior Disorder and Other Parasomnias
Parasomnias are sleep disorders that involve abnormal behaviors, emotional experiences, perceptions, and dream activity, occurring during specific sleep stages or sleep-wake transi...
1年前
AEON Biopharma Reports Disappointing Interim Phase 2 Results of Migraine Preventive ABP-450
Newly announced preliminary top-line results from a planned interim analysis of a phase 2 study (NCT04845178) showed that treatment with ABP-450 (AEON Biopharma) did not meet its p...
1年前
NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy
Chronic demyelinating polyneuropathy (CIDP) is a neuromuscular disorder characterized by progressive weakness and impaired sensory function in the arms and legs. It is an autoimmun...
1年前
SAGE-324/BIIB124 Significantly Reduces Upper Limb Tremor in Phase 2 KINETIC Trial
Helen Colquhoun, MD(Credit: LinkedIn)Recently published in Movement Disorders, results from the double-blind, randomized, placebo-controlled, phase 2 KINETIC trial (NCT04305275) as...
1年前
ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS
Jeremy M. Shefner, MD, PhDNewly announced analyses from the phase 2b PARADIGM trial (NCT05357950) showed that treatment with PrimeC (NeuroSense), an investigational agent made up o...
1年前Early Treatment Response and Safety Profile of AXS-05 in Phase 3 ACCORD Trial: Anton P. Porsteinsson, MD
WATCH TIME: 6 minutes'It's important because when patients finally seek treatment for agitation and aggression that’s been going on for quite a while and has gotten to a critical ...
1年前
